ESMO 2021 | ZENITH20-4: efficacy & safety of poziotinib in treatment-naïve NSCLC with HER2 exon 20 mutations

Robin Cornelissen, MD, PhD, Erasmus University Rotterdam, Rotterdam, Netherlands, presents the results from the ZENITH20-4 study (NCT03318939), a multinational Phase II study evaluating the efficacy and safety of poziotinib, a potent tyrosine kinase inhibitor, in newly diagnosed patients with non-small cell lung cancer (NSCLC) and HER2 exon 20 insertion mutations. In this study, poziotinib demonstrated clinically meaningful efficacy in newly diagnosed NSCLC patients with HER2 exon 20 mutations with a safety profile similar to other second generation tyrosine kinase inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.